Treatment of de novo myelodysplastic syndromes may include the following:

—      Supportive care with transfusion therapy.

—      High-dose chemotherapy with stem cell transplant using stem cells from a donor.

—      Supportive care with growth factor therapy.

—      Chemotherapy with azacitidine, decitabine, or other anticancer drugs.

—      Supportive care with drug therapy.

—      A clinical trial of a new anticancer drug.

—      A clinical trial of low- dose chemotherapy with stem cell transplant using stem cells from a donor.

This summary section refers to specific treatments under study in clinical trials, but it may not mention every new treatment being studied. Information about ongoing clinical trials is available from the NCI Web site ¹.

Check for clinical trials from NCI’s PDQ Cancer Clinical Trials Registry that are now accepting patients with de novo myelodysplastic syndromes ².

Secondary Myelodysplastic Syndromes

Treatment of secondary myelodysplastic syndromes may include the following:

—      Supportive care with transfusion therapy.

—      Supportive care with growth factor therapy.

—      Chemotherapy with azacitidine or other anticancer drugs.

—      Chemotherapy with stem cell transplant using stem cells from a donor.

—      A clinical trial of chemotherapy.

—      A clinical trial of low- dose chemotherapy with stem cell transplant using stem cells from a donor.

—      A clinical trial of supportive care with drug therapy.

This summary section refers to specific treatments under study in clinical trials, but it may not mention every new treatment being studied. Information about ongoing clinical trials is available from the NCI Web site ¹.

Check for clinical trials from NCI’s PDQ Cancer Clinical Trials Registry that are now accepting patients with secondary myelodysplastic syndromes ³.

Previously Treated Myelodysplastic Syndromes

Treatment of previously treated myelodysplastic syndromes may include the following:

—      High-dose chemotherapy with stem cell transplant using stem cells from a donor.

—      Chemotherapy with azacitidine or decitabine.

—      Supportive care with transfusion therapy, growth factor therapy, and/or drug therapy.

—      A clinical trial of low- dose chemotherapy with stem cell transplant using stem cells from a donor.

—      A clinical trial of new drug therapy.

This summary section refers to specific treatments under study in clinical trials, but it may not mention every new treatment being studied. Information about ongoing clinical trials is available from the NCI Web site ¹.

Check for clinical trials from NCI’s PDQ Cancer Clinical Trials Registry that are now accepting patients with previously treated myelodysplastic syndromes ⁴.